Compare Quest Diagnostics Inc (DGX) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs McDonald's Corp — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while McDonald's Corp trades at $235.23 (market cap $167.64B). The key difference: McDonald's Corp is far larger — about 6.6× Quest Diagnostics Inc's market cap, and McDonald's Corp pays the higher dividend (3.26%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and McDonald's Corp for 164 Days on average.
| DGX | MCD | |
|---|---|---|
Market Cap | $25.48B | $167.64B |
Volume | 941,866 | 11,320,306 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $341.06 |
52-Week Low | $173.49 | $230.88 |
Typical Hold Time | 56 Days | 164 Days |
Enterprise Value | $31.23B | $221.41B |
Dividend Yield | 1.49% | 3.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
McDonald's (MCD) trades at $236.9, up 2.61% today, but technical indicators signal a bearish trend. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.38 exceeding the $3.32 estimate. Revenue growth remains steady, reaching $26.89B in 2025, while net income margin stands at 31.72%. Recent news highlights the launch of the 'McDonald's NEXT' strategy focusing on automation and improved customer experience to drive growth amid competitive pressures.
The outlook for MCD is mixed: analyst consensus is bullish with a $284.70 price target, but technical weakness and inflation risks pose challenges. Investment appeal lies in its robust profitability and dividend payments, though high debt levels and margin pressures from rising costs require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
